MOH — authorised 22 March 1950
- Marketing authorisation holder: BAXTER HLTHCARE
- Status: likely_approved
🇮🇱 Wydase in Israel
MOH authorised Wydase on 22 March 1950
Marketing authorisation
Wydase in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in Israel
Frequently asked questions
Is Wydase approved in Israel?
Yes. MOH authorised it on 22 March 1950.
Who is the marketing authorisation holder for Wydase in Israel?
BAXTER HLTHCARE holds the Israeli marketing authorisation.